Literature DB >> 29433407

Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies.

Jing Zhang1, Chia-Wen Ko2, Lei Nie2, Yong Chen3, Ram Tiwari2.   

Abstract

Meta-analysis of interventions usually relies on randomized controlled trials. However, when the dominant source of information comes from single-arm studies, or when the results from randomized controlled trials lack generalization due to strict inclusion and exclusion criteria, it is vital to synthesize both sources of evidence. One challenge of synthesizing both sources is that single-arm studies are usually less reliable than randomized controlled trials due to selection bias and confounding factors. In this paper, we propose a Bayesian hierarchical framework for the purpose of bias reduction and efficiency gain. Under this framework, three methods are proposed: bivariate generalized linear mixed effects models, hierarchical power prior model and hierarchical commensurate prior model. Design difference and potential biases are considered in all models, within which the hierarchical power prior and hierarchical commensurate prior models further offer to downweight single-arm studies flexibly. The hierarchical commensurate prior model is recommended as the primary method for evidence synthesis because of its accuracy and robustness. We illustrate our methods by applying all models to two motivating datasets and evaluate their performance through simulation studies. We finish with a discussion of the advantages and limitations of our methods, as well as directions for future research in this area.

Entities:  

Keywords:  Evidence synthesis; Markov chain Monte Carlo; bias; different types of studies; downweighting; efficiency

Year:  2018        PMID: 29433407      PMCID: PMC6719559          DOI: 10.1177/0962280218754928

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  41 in total

1.  Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.

Authors:  Meg A Gamalo; Ram C Tiwari; Lisa M LaVange
Journal:  Pharm Stat       Date:  2013-08-05       Impact factor: 1.894

2.  Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.

Authors:  R Arranz; P García-Alfonso; P Sobrino; P Zamora; R Carrión; J García-Laraña; G Pérez; J López; E Lavilla; M Lozano; C Rayón; R Colomer; M G Barón; E Flores; G Pérez-Manga; J M Fernández-Rañada
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  Health services research: reporting on studies using secondary data sources.

Authors:  P Huston; C D Naylor
Journal:  CMAJ       Date:  1996-12-15       Impact factor: 8.262

4.  Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid.

Authors:  J A Hoek; M T Nurmohamed; K J Hamelynck; R K Marti; H C Knipscheer; H ten Cate; H R Büller; H N Magnani; J W ten Cate
Journal:  Thromb Haemost       Date:  1992-01-23       Impact factor: 5.249

5.  Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

Authors:  A Hagenbeek; P Carde; J H Meerwaldt; R Somers; J Thomas; R De Bock; J M Raemaekers; A van Hoof; C De Wolf-Peeters; M van Glabbeke
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Bayesian hierarchical models for network meta-analysis incorporating nonignorable missingness.

Authors:  Jing Zhang; Haitao Chu; Hwanhee Hong; Beth A Virnig; Bradley P Carlin
Journal:  Stat Methods Med Res       Date:  2015-07-28       Impact factor: 3.021

8.  Performing Arm-Based Network Meta-Analysis in R with the pcnetmeta Package.

Authors:  Lifeng Lin; Jing Zhang; James S Hodges; Haitao Chu
Journal:  J Stat Softw       Date:  2017-08-29       Impact factor: 6.440

9.  Absolute or relative effects? Arm-based synthesis of trial data.

Authors:  S Dias; A E Ades
Journal:  Res Synth Methods       Date:  2015-10-13       Impact factor: 5.273

10.  Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.

Authors:  Sofia Dias; Alex J Sutton; A E Ades; Nicky J Welton
Journal:  Med Decis Making       Date:  2012-10-26       Impact factor: 2.583

View more
  4 in total

1.  A Systematic Risk Assessment and Meta-Analysis on the Use of Oral β-Alanine Supplementation.

Authors:  Eimear Dolan; Paul A Swinton; Vitor de Salles Painelli; Benedict Stephens Hemingway; Bruna Mazzolani; Fabiana Infante Smaira; Bryan Saunders; Guilherme G Artioli; Bruno Gualano
Journal:  Adv Nutr       Date:  2019-05-01       Impact factor: 8.701

2.  BRIDGING RANDOMIZED CONTROLLED TRIALS AND SINGLE-ARM TRIALS USING COMMENSURATE PRIORS IN ARM-BASED NETWORK META-ANALYSIS.

Authors:  Zhenxun Wang; Lifeng Lin; Thomas Murray; James S Hodges; Haitao Chu
Journal:  Ann Appl Stat       Date:  2021-12-21       Impact factor: 1.959

3.  Incorporating single-arm studies in meta-analysis of randomised controlled trials: a simulation study.

Authors:  Janharpreet Singh; Keith R Abrams; Sylwia Bujkiewicz
Journal:  BMC Med Res Methodol       Date:  2021-06-03       Impact factor: 4.615

4.  Bayesian network meta-analysis methods for combining individual participant data and aggregate data from single arm trials and randomised controlled trials.

Authors:  Janharpreet Singh; Sandro Gsteiger; Lorna Wheaton; Richard D Riley; Keith R Abrams; Clare L Gillies; Sylwia Bujkiewicz
Journal:  BMC Med Res Methodol       Date:  2022-07-11       Impact factor: 4.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.